Header Logo

Connection

Theo Manschreck to Cognition Disorders

This is a "connection" page, showing publications Theo Manschreck has written about Cognition Disorders.
Connection Strength

0.819
  1. Manschreck TC, Maher BA, Winzig L, Candela SF, Beaudette S, Boshes R. Age disorientation in schizophrenia: an indicator of progressive and severe psychopathology, not institutional isolation. J Neuropsychiatry Clin Neurosci. 2000; 12(3):350-8.
    View in: PubMed
    Score: 0.181
  2. Boshes RA, Manschreck TC. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia. Med Hypotheses. 2016 May; 90:79-81.
    View in: PubMed
    Score: 0.139
  3. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders. Biol Psychiatry. 1990 Jan 15; 27(2):150-8.
    View in: PubMed
    Score: 0.091
  4. Chan RC, Wang Y, Wang L, Chen EY, Manschreck TC, Li ZJ, Yu X, Gong QY. Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design. PLoS One. 2009 Dec 24; 4(12):e8469.
    View in: PubMed
    Score: 0.090
  5. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
    View in: PubMed
    Score: 0.075
  6. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 Sep; 31(9):2033-46.
    View in: PubMed
    Score: 0.070
  7. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
    View in: PubMed
    Score: 0.067
  8. Maher BA, Manschreck TC, Redmond D, Beaudette S. Length of illness and the gradient from positive to negative semantic priming in schizophrenic patients. Schizophr Res. 1996 Nov 15; 22(2):127-32.
    View in: PubMed
    Score: 0.036
  9. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res. 2011 Aug; 130(1-3):47-52.
    View in: PubMed
    Score: 0.025
  10. Maher BA, Manschreck TC, Linnet J, Candela S. Quantitative assessment of the frequency of normal associations in the utterances of schizophrenia patients and healthy controls. Schizophr Res. 2005 Oct 15; 78(2-3):219-24.
    View in: PubMed
    Score: 0.017
  11. Manschreck TC, Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry. 1984 May; 19(5):703-19.
    View in: PubMed
    Score: 0.015
  12. Maher BA, Manschreck TC, Rucklos ME. Contextual constraint and the recall of verbal material in schizophrenia: the effect of thought disorder. Br J Psychiatry. 1980 Jul; 137:69-73.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.